Position in ANL
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$36,946,406
+$14,714,308 QoQ
Shares Held
3,212,731
0.0% QoQ
Ownership
4.99%
of shares outstanding
% of Portfolio
1.12%
of 13F equity value
Holder Rank
#2
of 42 holders
Holding Since
Mar 2026
2 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ANL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Venrock Adviser, LLC holds $3,294,790,938 across 31 Biotechnology names. ANL ranks #19 (1.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | 8,493,321 | $1,127,318,496 | |||
| 2 | ORKA |
Oruka Therapeutics, Inc.
|
4,148,428 | $394,805,892 | |
| 3 | ERAS |
Erasca, Inc.
|
17,891,812 | $327,777,995 | |
| 4 | SYRE |
Spyre Therapeutics, Inc.
|
2,985,448 | $265,048,073 | |
| 5 | DNTH |
Dianthus Therapeutics, Inc. /DE/
|
1,180,000 | $115,026,400 | |
| 6 | OCUL |
Ocular Therapeutix, Inc
|
10,346,926 | $101,606,813 | |
| 7 | DMRA |
Damora Therapeutics, Inc.
|
3,603,595 | $93,729,505 | |
| 8 | SVRA |
Savara Inc
|
14,745,943 | $90,835,008 |
All Filings in ANL
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $36,946,406 | 3,212,731 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $22,232,098 | 3,212,731 | Shares | Sole | 2026-05-15 | |
| No filing history on record for this holder in this stock. | ||||||